Irhythm Technologies (IRTC) | Financial Analysis & Statements
Irhythm Technologies Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
208.9M
Gross Profit
148.1M
70.88%
Operating Income
5.0M
2.40%
Net Income
5.6M
2.67%
EPS (Diluted)
$0.17
Balance Sheet Metrics
Total Assets
1.0B
Total Liabilities
867.3M
Shareholders Equity
152.7M
Debt to Equity
5.68
Cash Flow Metrics
Operating Cash Flow
11.7M
Free Cash Flow
14.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Irhythm Technologies Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 747.1M | 591.8M | 492.7M | 410.9M | 322.8M |
| Cost of Goods Sold | 219.9M | 184.3M | 160.9M | 129.3M | 109.3M |
| Gross Profit | 527.2M | 407.5M | 331.8M | 281.6M | 213.6M |
| Gross Margin % | 70.6% | 68.9% | 67.3% | 68.5% | 66.2% |
| Operating Expenses | |||||
| Research & Development | 84.6M | 103.8M | 60.2M | 46.6M | 38.7M |
| Selling, General & Administrative | 492.6M | 418.6M | 385.6M | 322.2M | 274.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 577.2M | 522.4M | 445.9M | 368.8M | 313.5M |
| Operating Income | -49.9M | -114.9M | -114.1M | -87.2M | -99.9M |
| Operating Margin % | -6.7% | -19.4% | -23.2% | -21.2% | -31.0% |
| Non-Operating Items | |||||
| Interest Income | 21.5M | 21.9M | 6.2M | 2.0M | 118.0K |
| Interest Expense | 13.2M | 12.8M | 3.6M | 4.1M | 1.2M |
| Other Non-Operating Income | -2.1M | -7.0M | -11.1M | -26.6M | 118.0K |
| Pre-tax Income | -43.6M | -112.7M | -122.7M | -115.9M | -101.0M |
| Income Tax | 953.0K | 565.0K | 750.0K | 269.0K | 367.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -44.6M | -113.3M | -123.4M | -116.2M | -101.4M |
| Net Margin % | -6.0% | -19.1% | -25.0% | -28.3% | -31.4% |
| Key Metrics | |||||
| EBITDA | 3.5M | -65.9M | -85.8M | -65.5M | -83.2M |
| EPS (Basic) | $-1.39 | $-3.63 | $-4.04 | $-3.88 | $-3.46 |
| EPS (Diluted) | $-1.39 | $-3.63 | $-4.04 | $-3.88 | $-3.46 |
| Basic Shares Outstanding | 32004000 | 31196000 | 30528000 | 29916000 | 29331000 |
| Diluted Shares Outstanding | 32004000 | 31196000 | 30528000 | 29916000 | 29331000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Irhythm Technologies Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 236.0M | 419.6M | 36.2M | 78.8M | 127.6M |
| Short-term Investments | 347.8M | 116.0M | 97.6M | 134.3M | 111.6M |
| Accounts Receivable | 75.7M | 79.9M | 61.5M | 49.9M | 46.4M |
| Inventory | 21.6M | 14.0M | 14.0M | 15.2M | 10.3M |
| Other Current Assets | 21.7M | 16.3M | 21.6M | 10.6M | 9.7M |
| Total Current Assets | 702.8M | 645.8M | 230.8M | 288.8M | 305.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 59.4M | 57.3M | 55.3M | 65.6M | 87.8M |
| Goodwill | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 53.1M | 50.2M | 48.0M | 22.3M | 16.1M |
| Total Non-Current Assets | 317.3M | 285.6M | 202.3M | 159.4M | 157.4M |
| Total Assets | 1.0B | 931.4M | 433.1M | 448.2M | 463.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.3M | 7.2M | 5.5M | 7.5M | 10.5M |
| Short-term Debt | 16.7M | 15.9M | 15.2M | 13.0M | 22.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 151.9M | 110.9M | 107.4M | 89.1M | 87.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 714.5M | 721.0M | 114.7M | 118.0M | 94.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 908.0K | 8.6M | 1.0M | 1.3M | 697.0K |
| Total Non-Current Liabilities | 715.4M | 729.6M | 115.7M | 119.3M | 95.6M |
| Total Liabilities | 867.3M | 840.5M | 223.0M | 208.4M | 183.5M |
| Equity | |||||
| Common Stock | 32.0K | 31.0K | 31.0K | 28.0K | 27.0K |
| Retained Earnings | -803.4M | -758.9M | -645.6M | -522.2M | -406.0M |
| Treasury Stock | 25.0M | 25.0M | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 152.7M | 90.9M | 210.1M | 239.8M | 279.5M |
| Key Metrics | |||||
| Total Debt | 731.2M | 736.9M | 129.8M | 131.0M | 117.7M |
| Working Capital | 550.9M | 534.9M | 123.4M | 199.7M | 217.7M |
Balance Sheet Composition
Irhythm Technologies Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -44.6M | -113.3M | -123.4M | -116.2M | -101.4M |
| Depreciation & Amortization | 26.5M | 25.8M | 22.1M | 19.6M | 16.6M |
| Stock-Based Compensation | 88.3M | 76.0M | 77.2M | 57.7M | 54.5M |
| Working Capital Changes | -114.4M | -97.0M | -110.3M | -79.1M | -51.8M |
| Operating Cash Flow | -37.1M | -72.9M | -134.0M | -117.7M | -75.3M |
| Investing Activities | |||||
| Capital Expenditures | -46.3M | -33.9M | -40.4M | -29.8M | -28.1M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -468.4M | -175.2M | -167.3M | -188.6M | -122.2M |
| Investment Sales | 237.7M | 101.2M | 206.5M | 166.0M | 255.5M |
| Investing Cash Flow | -277.1M | -108.0M | -1.2M | -52.4M | 105.3M |
| Financing Activities | |||||
| Share Repurchases | 0 | -25.0M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 736.2M | 0 | 35.0M | 0 |
| Debt Repayment | 0 | -116.4M | 0 | -21.4M | -11.7M |
| Financing Cash Flow | 0 | 502.9M | 0 | 13.5M | -37.5M |
| Free Cash Flow | 34.5M | -45.6M | -90.5M | -52.8M | -65.8M |
| Net Change in Cash | -314.1M | 322.0M | -135.2M | -156.6M | -7.6M |
Cash Flow Trend
Irhythm Technologies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-87.47
Forward P/E
142.14
Price to Book
25.14
Price to Sales
5.23
PEG Ratio
0.17
Profitability Ratios
Profit Margin
-5.96%
Operating Margin
4.20%
Return on Equity
-36.57%
Return on Assets
-2.36%
Financial Health
Current Ratio
4.63
Debt to Equity
478.69
Beta
1.18
Per Share Data
EPS (TTM)
$-1.39
Book Value per Share
$4.73
Revenue per Share
$23.35
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IRTC | 4.0B | -87.47 | 25.14 | -36.57% | -5.96% | 478.69 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Masimo | 9.4B | 46.47 | 12.89 | 23.43% | -9.92% | 77.55 |
| Bio-Rad | 8.1B | 10.75 | 1.08 | 10.84% | 29.42% | 18.58 |
| Bio-Rad Laboratories | 7.6B | 10.98 | 1.11 | 10.84% | 29.42% | 18.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.






